Change Is Happening in the EU: What Pharma Companies Need to Know About the European Union’s New Pharmaceutical Strategy

For the first time, the European Union is undergoing a major overhaul of its pharmaceutical industry with the new Pharmaceutical Strategy for Europe, which was launched in late 2020.   

Through this strategy, the European Union (EU) is making changes to its infrastructure with the goal of building a holistic, patient-centered, forward-looking pharmaceutical landscape for all EU member countries and patients. 

Focusing on patient access, treatment affordability and sustainable innovation, the European Commission outlines four key areas in which they will take legislative and non-legislative actions to move this progressive, patient-centric plan forward:  

  1. Delivering for patients: Fulfilling unmet medical needs and ensuring accessibility and affordability of medicines   
  2. Supporting a competitive and innovative European pharmaceutical industry  
  3. Enhancing resilience: A diversified and secure supply chain, environmentally sustainable pharmaceuticals, crisis preparedness and response mechanisms  
  4. Ensuring a strong EU voice in the pharmaceutical industry globally  

For manufacturers, now is the time to pay attention, realign drug research and development and reconsider commercialisation strategies. Many changes that will reshaphow companies commercialise in Europe will soon be on their way, with 30 new strategy initiatives and actions taking place this year.  

If pharma companies want to remain globally relevant and competitive, they must take a hard look at their development and commercialisation strategies – particularly related to clinical trials, pricing, and digital technologies and therapeutics – starting now. 

In this article, Mike Ryan (Executive Vice President, Europe), Ed Corbett (Senior Principal, Head of EMEA, EVERSANA™ CONSULTING) and Alan Crowther (General Manager, Global Pricing, Access and Digital Solutions) address key elements of the Pharmaceutical Strategy for Europe and outline actions that pharma companies must take to prepare for new EU initiatives. But above all, they underscore the true purpose of the strategy: to make drugs cheaper and more accessible to all EU citizens and to make the process of commercialisation simpler and more profitable for pharma. 

Download the full article below. 

To learn more about global change coming to pharma, watch the latest webinar: How to Determine Price and Global Launch Sequence in a Post-COVID World  

 

Author
Ed Corbett
Senior Principal, Head of EMEA, EVERSANA™ CONSULTING

As the lead for EVERSANA’s EMEA management consulting practice, Ed specializes in commercial and corporate strategy and has significant national and global launch experience. He has helped a diverse set of clients from big…

Mike Ryan
Executive Vice President, Europe

With more than 25 years of experience in the life science industry, Mike has held global leadership positions in both clinical development and life-sciences software companies. Given this experience, he is highly experienced in…

Alan Crowther
General Manager, Global Pricing, Access and Digital Solutions

Alan has spent close to 20 years doing commercial work for the life sciences industry. His experience includes creating innovative solutions for global pricing and access, including work on price optimization, global data collection…